Skip to main content

TNF inhibitor

      Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated. 
      The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
      Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow

      We get int

      Eric Dein

      1 year 10 months ago
      Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
      Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
      #ACR23 highlights from PlenaryII
      πŸ™‰#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause

      Janet Pope

      1 year 10 months ago
      #ACR23 highlights from PlenaryII πŸ™‰#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it. πŸ™‰Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP #ACR23 @RheumNow @ACRheum #ACRbest
      Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%)

      Dr. Antoni Chan

      1 year 10 months ago
      Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%). These results are driven by the severity of the disease of patients on JAKi compared to other MOA. Aymon R Abst#1692 #ACR23 @RheumNow https://t.co/LPDpWdjoLg https://t.co/Ztaz94omd9
      Obs study, bDMARDs & malignancy

      TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs

      I'm a little

      Mike Putman EBRheum

      1 year 10 months ago
      Obs study, bDMARDs & malignancy TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs I'm a little skeptical... KM curves diverged w/~45 days, seems implausible? Agree w/first author, possible channeling bias @RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
      Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR

      Richard Conway

      1 year 10 months ago
      Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR 2.2 (1.5, 3.3) ABA HR 1.7 (1.3-2.4), JAKi HR 1.3 (0.9-1.9). Abstr#1678 #ACR23 @RheumNow https://t.co/bTNtaNJrln https://t.co/qQBM2F2q8N
      Ritux (OR 2.2), ABA (OR 1.3), JAKi (OR 1.3) significantly increase risk of cancer vs. TNFi

      Cohort of 37000+ RA pts star

      Aurelie Najm

      1 year 10 months ago
      Ritux (OR 2.2), ABA (OR 1.3), JAKi (OR 1.3) significantly increase risk of cancer vs. TNFi Cohort of 37000+ RA pts starting bio/tsDMARDs (379 incident cancers) True biologic effect or confounding by indication in a generally more comorbid population? @RheumNow #ACR23 ABST1678 https://t.co/suj6mVBEC0
      Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
      Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media.  Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more. 
      Large observational study of TNF use among patients with RA & cancer

      Overall encouraging, no negative impact on sur

      Mike Putman EBRheum

      1 year 10 months ago
      Large observational study of TNF use among patients with RA & cancer Overall encouraging, no negative impact on survival I'm kind of a TNF-truther on this; I don't think they cause ANY increased risk of malignancy @RheumNow #ACR23 Abstr 1675 https://t.co/KRVlIFxhl8
      2 RA cohorts w/Breast Cancer

      17% TNFi within 1yr after surgery

      No diff in overall survival at 5 yr w/ TNFi or csDMARD

      Aurelie Najm

      1 year 10 months ago
      2 RA cohorts w/Breast Cancer 17% TNFi within 1yr after surgery No diff in overall survival at 5 yr w/ TNFi or csDMARD Trend towards better BC specific survival w/ TNFi vs. csDMARD only Worst survival for GC>7.5mg/day Only 2 yrs follow up @RheumNow #ACR23 ABST1675 https://t.co/ekKlJ2dP5i
      Does TNFi use in pts with RA and early breast cancer affect survival?
      TNFi did not affect overall survival or breast ca

      Robert B Chao, MD

      1 year 10 months ago
      Does TNFi use in pts with RA and early breast cancer affect survival? TNFi did not affect overall survival or breast cancer specific survival compared to cDMARDs Steroids did increase mortality @RheumNow #ACR23 Abs#1675
      ×